Baseline demographics, clinical and laboratory variables of patients with sickle cell anemia in the pooled cohorts
| Variables . | CKD-EPI–2009 . | CKD-EPI–2021 . | ||
|---|---|---|---|---|
| n . | Median (IQR) or n (%) . | n . | Median (IQR) or n (%) . | |
| Age, y | 506 | 24 (19-34) | 516 | 25.0 (19.0-34.0) |
| Sex (female) | 506 | 268 (52.96) | 516 | 273 (52.91) |
| Weight, kg | 465 | 64.9 (57.5-73.9) | 475 | 65.0 (57.5-74.2) |
| Height, cm | 212 | 169.1 (163.15-175.75) | 218 | 169.1 (163.3-175.7) |
| Body mass index, kg/m2 | 206 | 21.9 (20.2-24.4) | 212 | 22.0 (20.2-24.8) |
| Systolic blood pressure, mm Hg | 478 | 117 (109-126) | 488 | 117 (109-126) |
| Diastolic blood pressure, mm Hg | 478 | 68 (60-74) | 488 | 68 (60-74) |
| White blood cell count, 109/L | 468 | 10.6 (8.0-13.1) | 478 | 10.6 (7.93-13.1) |
| Hemoglobin, g/dL | 468 | 9.1 (8.02-10.07) | 478 | 9.0 (8.0-10.0) |
| Hematocrit, % | 466 | 26.37 (23.3-29.2) | 476 | 26.33 (23.25-29.1) |
| Reticulocyte count, 109/L | 372 | 268.23 (187.33-380.35) | 382 | 267.4 (186.67-380.2) |
| eGFR, mL/min per 1.73 m2 | 506 | 129.3 (118.4-137.6) | 516 | 129.1 (117.4-137.4) |
| Blood urea nitrogen, mg/dL | 255 | 7.0 (5.0-9.0) | 264 | 7.0 (5.0-9.0) |
| Lactate dehydrogenase, U/L | 400 | 721.0 (417.5-1084.5) | 409 | 717 (416-1066) |
| Total bilirubin, mg/dL | 440 | 2.60 (1.60-4.20) | 450 | 2.55 (1.60-4.20) |
| Indirect bilirubin, mg/dL | 177 | 2.30 (1.60-3.71) | 183 | 2.30 (1.60-3.71) |
| Direct bilirubin, mg/dL | 176 | 0.30 (0.20-0.45) | 182 | 0.30 (0.20-0.50) |
| Ferritin, µg/L | 265 | 487.0 (146.0-1258.0) | 272 | 474.5 (139.5-1267.0) |
| Fetal hemoglobin, % | 309 | 7.80 (3.90-14.20) | 318 | 7.70 (3.90-14.1) |
| Urine specific gravity | 106 | 1.01 (1.01-1.01) | 107 | 1.01 (1.01-1.01) |
| Proteinuria (yes) | 259 | 48 (18.5) | 262 | 49 (18.7) |
| Hemoglobinuria (yes) | 295 | 42 (14.2) | 303 | 45 (14.9) |
| History of acute chest syndrome | 476 | 360 (75.6) | 485 | 366 (75.5) |
| History of stroke | 465 | 86 (18.5) | 474 | 88 (18.6) |
| History of leg ulcers | 445 | 55 (12.4) | 455 | 60 (13.2) |
| History of avascular necrosis | 342 | 118 (34.5) | 352 | 125 (35.5) |
| History of priapism | 170 | 69 (40.6) | 174 | 70 (40.2) |
| History of diabetes | 462 | 6 (1.3) | 472 | 7 (1.5) |
| Chronic RBC transfusion | 480 | 50 (10.4) | 490 | 50 (10.2) |
| Hydroxyurea therapy | 504 | 272 (54.0) | 514 | 277 (53.9) |
| ACE-I/ARB therapy | 263 | 17 (6.5) | 272 | 19 (7.0) |
| Variables . | CKD-EPI–2009 . | CKD-EPI–2021 . | ||
|---|---|---|---|---|
| n . | Median (IQR) or n (%) . | n . | Median (IQR) or n (%) . | |
| Age, y | 506 | 24 (19-34) | 516 | 25.0 (19.0-34.0) |
| Sex (female) | 506 | 268 (52.96) | 516 | 273 (52.91) |
| Weight, kg | 465 | 64.9 (57.5-73.9) | 475 | 65.0 (57.5-74.2) |
| Height, cm | 212 | 169.1 (163.15-175.75) | 218 | 169.1 (163.3-175.7) |
| Body mass index, kg/m2 | 206 | 21.9 (20.2-24.4) | 212 | 22.0 (20.2-24.8) |
| Systolic blood pressure, mm Hg | 478 | 117 (109-126) | 488 | 117 (109-126) |
| Diastolic blood pressure, mm Hg | 478 | 68 (60-74) | 488 | 68 (60-74) |
| White blood cell count, 109/L | 468 | 10.6 (8.0-13.1) | 478 | 10.6 (7.93-13.1) |
| Hemoglobin, g/dL | 468 | 9.1 (8.02-10.07) | 478 | 9.0 (8.0-10.0) |
| Hematocrit, % | 466 | 26.37 (23.3-29.2) | 476 | 26.33 (23.25-29.1) |
| Reticulocyte count, 109/L | 372 | 268.23 (187.33-380.35) | 382 | 267.4 (186.67-380.2) |
| eGFR, mL/min per 1.73 m2 | 506 | 129.3 (118.4-137.6) | 516 | 129.1 (117.4-137.4) |
| Blood urea nitrogen, mg/dL | 255 | 7.0 (5.0-9.0) | 264 | 7.0 (5.0-9.0) |
| Lactate dehydrogenase, U/L | 400 | 721.0 (417.5-1084.5) | 409 | 717 (416-1066) |
| Total bilirubin, mg/dL | 440 | 2.60 (1.60-4.20) | 450 | 2.55 (1.60-4.20) |
| Indirect bilirubin, mg/dL | 177 | 2.30 (1.60-3.71) | 183 | 2.30 (1.60-3.71) |
| Direct bilirubin, mg/dL | 176 | 0.30 (0.20-0.45) | 182 | 0.30 (0.20-0.50) |
| Ferritin, µg/L | 265 | 487.0 (146.0-1258.0) | 272 | 474.5 (139.5-1267.0) |
| Fetal hemoglobin, % | 309 | 7.80 (3.90-14.20) | 318 | 7.70 (3.90-14.1) |
| Urine specific gravity | 106 | 1.01 (1.01-1.01) | 107 | 1.01 (1.01-1.01) |
| Proteinuria (yes) | 259 | 48 (18.5) | 262 | 49 (18.7) |
| Hemoglobinuria (yes) | 295 | 42 (14.2) | 303 | 45 (14.9) |
| History of acute chest syndrome | 476 | 360 (75.6) | 485 | 366 (75.5) |
| History of stroke | 465 | 86 (18.5) | 474 | 88 (18.6) |
| History of leg ulcers | 445 | 55 (12.4) | 455 | 60 (13.2) |
| History of avascular necrosis | 342 | 118 (34.5) | 352 | 125 (35.5) |
| History of priapism | 170 | 69 (40.6) | 174 | 70 (40.2) |
| History of diabetes | 462 | 6 (1.3) | 472 | 7 (1.5) |
| Chronic RBC transfusion | 480 | 50 (10.4) | 490 | 50 (10.2) |
| Hydroxyurea therapy | 504 | 272 (54.0) | 514 | 277 (53.9) |
| ACE-I/ARB therapy | 263 | 17 (6.5) | 272 | 19 (7.0) |
The number of evaluated patients for both equations differs due to different numbers of eligible patients based on eGFR.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD-EPI-2009, Chronic Kidney Disease Epidemiology Collaboration formula for estimated glomerular filtration rate (omitting adjustment for the Black race), utilizing serum creatinine; CKD-EPI-2021, Chronic Kidney Disease Epidemiology Collaboration formula for estimated glomerular filtration rate, utilizing serum creatinine.